Raku Co..Ltd AI Stock Analysis
Raku Co..Ltd (4154) AI Stock Analysis
Raku Co..Ltd
(TPEx:4154)
The score is driven primarily by severe financial deterioration: a revenue base that has shrunk by more than 95% over five years, negative gross profit for three straight years, persistent net losses, and accelerating cash burn with negative free cash flow in five of the last six years. A near debt-free balance sheet with equity covering roughly 60% of assets and narrowing losses from cost cutting provide some cushion, but that equity is being consumed by operations rather than grown. Technicals reinforce the caution, with the price below all key moving averages and negative MACD momentum. Valuation adds no offset, as the P/E is negative and there is no dividend. A sustained turnaround would require revenue stabilisation and a return to positive gross margins.
Raku Co..Ltd (4154) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 418.45M
- Dividend Yield
- ―
- Average Volume (3M)
- 16.22K
- Price to Earnings (P/E)
- -15.0
- Beta (1Y)
- 0.07
- Revenue Growth
- 49.97%
- EPS Growth
- 76.21%
- Country
- TW
- Employees
- 75
- Sector
- General
- Sector Strength
- 55
- Industry
- Beverages - Non-Alcoholic
Raku Co..Ltd Business Overview & Revenue Model
Company Description
Raku Co., Ltd operates a diverse business portfolio, with its boutique accessories division serving customers across Malaysia, Singapore, China, Taiwan, Thailand, Europe, and other global markets. The company's operations are structured into multiple...
Raku Co..Ltd Financial Statement Overview
Summary
Financials are in deep distress. Revenue has collapsed over 95% in five years to roughly NT$27 million, gross profit has been negative for three consecutive years (about -74% gross margin), and operating margin is near -242%. Operating cash flow has worsened to -NT$68 million with free cash flow of -NT$69 million, marking negative free cash flow in five of the last six years. The one genuine offset is a conservative balance sheet: total debt cut to about NT$7 million (debt-to-equity of 0.03), equity near NT$222 million covering roughly 60% of assets, plus narrowing net and operating losses from cost cutting. However, shrinking assets, an eroding equity base, and ROE around -27% leave no visible path to breakeven.
Income Statement
7Very NegativeBalance Sheet
46NeutralCash Flow
11Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.80M | 26.76M | 41.37M | 279.34M | 439.56M | 400.71M |
| Gross Profit | 4.29M | -19.89M | -49.08M | -43.43M | 41.17M | 18.03M |
| EBITDA | -15.04M | -46.81M | -101.57M | -70.56M | -1.30M | -55.52M |
| Net Income | -38.42M | -60.57M | -124.79M | -108.82M | -34.94M | -68.87M |
Balance Sheet | ||||||
| Total Assets | 395.12M | 372.79M | 457.89M | 485.65M | 845.82M | 677.28M |
| Cash, Cash Equivalents and Short-Term Investments | 67.03M | 73.49M | 163.44M | 119.71M | 226.90M | 212.73M |
| Total Debt | 91.67M | 7.10M | 94.30M | 5.85M | 207.04M | 90.24M |
| Total Liabilities | 144.31M | 136.87M | 223.44M | 242.92M | 477.32M | 279.52M |
| Stockholders Equity | 237.65M | 222.44M | 221.24M | 213.36M | 317.12M | 331.34M |
Cash Flow | ||||||
| Free Cash Flow | -37.77M | -68.89M | -49.32M | 48.01M | -105.30M | -183.53M |
| Operating Cash Flow | -36.64M | -68.19M | -38.07M | 56.40M | -7.46M | 5.31M |
| Investing Cash Flow | -73.55M | -35.65M | -8.12M | 49.08M | -104.51M | -190.53M |
| Financing Cash Flow | 28.87M | -11.30M | 87.64M | -184.75M | 101.17M | 238.65M |
Raku Co..Ltd Peers Comparison
Overall Rating
TW:419246Neutral
TW:178135Underperform- TW:415428Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4192 | 46Neutral | TWD 563.91M | -0.01 | ― | ― | -1.68% | -5.45% |
| TW:1781 | 35Underperform | TWD 407.71M | -8.04 | ― | ― | -12.12% | -17.29% |
| TW:4154 | 28Underperform | TWD 420.37M | -15.00 | ― | ― | 49.97% | 76.21% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4154 | Raku Co..Ltd | 10.75 | -5.75 | -34.85% | |
| TW:1781 | Health & Life Co., Ltd. | 8.60 | -3.40 | -28.33% | |
| TW:4192 | SynCore Biotechnology Co., Ltd. | 15.95 | -9.55 | -37.45% | |
| TW:6549 | TaiwanJ Pharmaceuticals Co., Ltd. | 6.25 | -1.47 | -19.04% | |
| TW:6621 | Unipharma Co., Ltd. | 12.00 | -0.35 | -2.83% | |
| TW:7891 | BoYen Therapeutics, Inc. | 23.45 | -8.00 | -25.44% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026